Cargando…
Human CXCR5(+)PD‐1(+) CD8 T cells in healthy individuals and patients with hematologic malignancies
Immune checkpoint blockade (ICB) has revolutionized cancer therapy, but varying response rates illustrate the need for biomarkers of response. Studies in mice have identified a subset of CD8 T cells that is essential for response to PD‐1 ICB. These CD8 T cells co‐express CXCR5, PD‐1 and Tcf1, and pr...
Autores principales: | Hofland, Tom, Martens, Anne W.J., van Bruggen, Jaco A.C., de Boer, Renate, Schetters, Sjoerd, Remmerswaal, Ester B.M., Bemelman, Frederike J., Levin, Mark‐David, Bins, Adriaan D., Eldering, Eric, Kater, Arnon P., Tonino, Sanne H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984320/ https://www.ncbi.nlm.nih.gov/pubmed/33098668 http://dx.doi.org/10.1002/eji.202048761 |
Ejemplares similares
-
Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
por: Hofland, Tom, et al.
Publicado: (2019) -
Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma
por: van Bruggen, Jaco A. C., et al.
Publicado: (2020) -
Correction: van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837
por: van Bruggen, Jaco A. C., et al.
Publicado: (2021) -
Functional Differences Between EBV- and CMV-Specific CD8(+) T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL
por: Hofland, Tom, et al.
Publicado: (2020) -
Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling
por: Hofland, Tom, et al.
Publicado: (2019)